Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities

Germán Calderillo; Matías Muñoz-Medel; Edelmira Carbajal; Miguel Córdova-Delgado; Doris Durán; Ignacio N. Retamal; Piga Fernández; Absalón Espinoza; Rodrigo Salas; María De La Paz Mastretta; Héctor Galindo; Bruno Nervi; Jorge Madrid; Cesar Sánchez; Carolina Ibáñez; José Peña; Sebastián Mondaca; Francisco Acevedo; Erica Koch; Mauricio P. Pinto; Marcelo Garrido

doi:10.1200/JGO.19.00410

Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities

Germán Calderillo, Matías Muñoz-Medel, Edelmira Carbajal, Miguel Córdova-Delgado, Doris Durán, Ignacio N. Retamal, Piga Fernández, Absalón Espinoza, Rodrigo Salas, María De La Paz Mastretta, Héctor Galindo, Bruno Nervi, Jorge Madrid, Cesar Sánchez, Carolina Ibáñez, José Peña, Sebastián Mondaca, Francisco Acevedo, Erica Koch, Mauricio P. PintoMarcelo Garrido^*

^*Corresponding author for this work

Facultad de Odontología

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. Patients and Methods: Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. Results: Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. Conclusion: To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias.

Original language	English
Pages (from-to)	647-657
Number of pages	11
Journal	JCO Global Oncology
Issue number	6
DOIs	https://doi.org/10.1200/JGO.19.00410
State	Published - 23 Apr 2020

Bibliographical note

Funding Information:
This study included clinical data from a total of 624 patients with GIST; 521 patients were contributed by the Fundación GIST Mexico and 103 by Fundación GIST Chile. This joint work is the result of the Salud con Datos initiative, which was initially formed by both advocacy groups as part of Alianza GIST, a Latin American nonprofit organization focused on the development of research, public policies, and improved access to specific treatments for Latin American patients with GIST. The registry was funded by the Life Raft Group, an international, nonprofit patient advocacy organization created to enhance survival and quality of life for people living with GIST through patient-powered research, education, and empowerment and global advocacy efforts. Life Raft Group had no access to patient raw data and did not participate in the database setup, data acquisition, or analysis during this study. This study was designed as an observational, multicenter, retrospective registry and was approved by the institutional review board and ethics committee of all participating institutions, following the Declaration of Helsinki, Good Clinical Practices, and both Mexican and Chilean regulations. Written informed consent was obtained from all participating patients.

Publisher Copyright:
Copyright © 2020 American Society of Clinical Oncology.

Keywords

Gastrointestinal stromal tumors
Neoplasm recurrence
Registries

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JGO.19.00410

Cite this

Calderillo, G., Muñoz-Medel, M., Carbajal, E., Córdova-Delgado, M., Durán, D., Retamal, I. N., Fernández, P., Espinoza, A., Salas, R., De La Paz Mastretta, M., Galindo, H., Nervi, B., Madrid, J., Sánchez, C., Ibáñez, C., Peña, J., Mondaca, S., Acevedo, F., Koch, E., ... Garrido, M. (2020). Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities. JCO Global Oncology, (6), 647-657. https://doi.org/10.1200/JGO.19.00410

@article{0ec3620394904d458778fb7e83ea0e2f,

title = "Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities",

abstract = "Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. Patients and Methods: Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. Results: Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. Conclusion: To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias. ",

keywords = "Gastrointestinal stromal tumors, Neoplasm recurrence, Registries",

author = "Germ{\'a}n Calderillo and Mat{\'i}as Mu{\~n}oz-Medel and Edelmira Carbajal and Miguel C{\'o}rdova-Delgado and Doris Dur{\'a}n and Retamal, {Ignacio N.} and Piga Fern{\'a}ndez and Absal{\'o}n Espinoza and Rodrigo Salas and {De La Paz Mastretta}, Mar{\'i}a and H{\'e}ctor Galindo and Bruno Nervi and Jorge Madrid and Cesar S{\'a}nchez and Carolina Ib{\'a}{\~n}ez and Jos{\'e} Pe{\~n}a and Sebasti{\'a}n Mondaca and Francisco Acevedo and Erica Koch and Pinto, {Mauricio P.} and Marcelo Garrido",

note = "Funding Information: This study included clinical data from a total of 624 patients with GIST; 521 patients were contributed by the Fundaci{\'o}n GIST Mexico and 103 by Fundaci{\'o}n GIST Chile. This joint work is the result of the Salud con Datos initiative, which was initially formed by both advocacy groups as part of Alianza GIST, a Latin American nonprofit organization focused on the development of research, public policies, and improved access to specific treatments for Latin American patients with GIST. The registry was funded by the Life Raft Group, an international, nonprofit patient advocacy organization created to enhance survival and quality of life for people living with GIST through patient-powered research, education, and empowerment and global advocacy efforts. Life Raft Group had no access to patient raw data and did not participate in the database setup, data acquisition, or analysis during this study. This study was designed as an observational, multicenter, retrospective registry and was approved by the institutional review board and ethics committee of all participating institutions, following the Declaration of Helsinki, Good Clinical Practices, and both Mexican and Chilean regulations. Written informed consent was obtained from all participating patients. Publisher Copyright: Copyright {\textcopyright} 2020 American Society of Clinical Oncology.",

year = "2020",

month = apr,

day = "23",

doi = "10.1200/JGO.19.00410",

language = "English",

pages = "647--657",

journal = "JCO Global Oncology",

issn = "2378-9506",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "6",

}

Calderillo, G, Muñoz-Medel, M, Carbajal, E, Córdova-Delgado, M, Durán, D, Retamal, IN, Fernández, P, Espinoza, A, Salas, R, De La Paz Mastretta, M, Galindo, H, Nervi, B, Madrid, J, Sánchez, C, Ibáñez, C, Peña, J, Mondaca, S, Acevedo, F, Koch, E, Pinto, MP & Garrido, M 2020, 'Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities', JCO Global Oncology, no. 6, pp. 647-657. https://doi.org/10.1200/JGO.19.00410

TY - JOUR

T1 - Retrospective analysis of chilean and Mexican GI stromal tumor registries

T2 - A tale of two Latin American realities

AU - Calderillo, Germán

AU - Muñoz-Medel, Matías

AU - Carbajal, Edelmira

AU - Córdova-Delgado, Miguel

AU - Durán, Doris

AU - Retamal, Ignacio N.

AU - Fernández, Piga

AU - Espinoza, Absalón

AU - Salas, Rodrigo

AU - De La Paz Mastretta, María

AU - Galindo, Héctor

AU - Nervi, Bruno

AU - Madrid, Jorge

AU - Sánchez, Cesar

AU - Ibáñez, Carolina

AU - Peña, José

AU - Mondaca, Sebastián

AU - Acevedo, Francisco

AU - Koch, Erica

AU - Pinto, Mauricio P.

AU - Garrido, Marcelo

N1 - Funding Information: This study included clinical data from a total of 624 patients with GIST; 521 patients were contributed by the Fundación GIST Mexico and 103 by Fundación GIST Chile. This joint work is the result of the Salud con Datos initiative, which was initially formed by both advocacy groups as part of Alianza GIST, a Latin American nonprofit organization focused on the development of research, public policies, and improved access to specific treatments for Latin American patients with GIST. The registry was funded by the Life Raft Group, an international, nonprofit patient advocacy organization created to enhance survival and quality of life for people living with GIST through patient-powered research, education, and empowerment and global advocacy efforts. Life Raft Group had no access to patient raw data and did not participate in the database setup, data acquisition, or analysis during this study. This study was designed as an observational, multicenter, retrospective registry and was approved by the institutional review board and ethics committee of all participating institutions, following the Declaration of Helsinki, Good Clinical Practices, and both Mexican and Chilean regulations. Written informed consent was obtained from all participating patients. Publisher Copyright: Copyright © 2020 American Society of Clinical Oncology.

PY - 2020/4/23

Y1 - 2020/4/23

N2 - Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. Patients and Methods: Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. Results: Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. Conclusion: To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias.

AB - Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. Patients and Methods: Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. Results: Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. Conclusion: To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias.

KW - Gastrointestinal stromal tumors

KW - Neoplasm recurrence

KW - Registries

UR - http://www.scopus.com/inward/record.url?scp=85085908808&partnerID=8YFLogxK

U2 - 10.1200/JGO.19.00410

DO - 10.1200/JGO.19.00410

M3 - Article

C2 - 32324433

AN - SCOPUS:85085908808

SN - 2378-9506

SP - 647

EP - 657

JO - JCO Global Oncology

JF - JCO Global Oncology

IS - 6

ER -

Retrospective analysis of chilean and Mexican GI stromal tumor registries: A tale of two Latin American realities

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this